Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.48EUR
27 Jun 2019
Change (% chg)

€0.00 (+0.00%)
Prev Close
€2.48
Open
€2.47
Day's High
€2.49
Day's Low
€2.47
Volume
9,325
Avg. Vol
50,303
52-wk High
€3.30
52-wk Low
€2.41

About

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for... (more)

Overall

Beta: -0.07
Market Cap(Mil.): €207.19
Shares Outstanding(Mil.): 83.37
Dividend: --
Yield (%): --

Financials

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

02 May 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

May 2 British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

02 May 2019

Earnings vs. Estimates